Integrated Omics-Based Discovery of Bioactive Halogenated Metabolites from the Deep-Sea Streptomyces sp. B188M101
Marine Drugs · 2025
DOI: 10.3390/md23090362 ↗Kurz gefasst
Fachartikel in der Zeitschrift Marine Drugs, 2025. Verfasst von Emmanuel Tope Oluwabusola und 12 weiteren Autor:innen. Beteiligte Einrichtung: Marine Biodiscovery Centre, Department of Chemistry, University of Aberdeen, Aberdeen AB24 3FX, UK. Hauptthemen laut MEDLINE: Streptomyces, Anti-Bacterial Agents, Biological Products. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union's Horizon 2020 research and innovation programme, BBSRC UK ALERT-22 Scheme, European Union.
Abstract (Originalsprache)
Using the one-strain-many-compounds (OSMAC) culturing approach, metabolomic studies, and bioassay-guided purification, we have isolated and characterised three new chlorinated natural products, agelolines B-D (1–3), together with two known compounds, ageloline A (4) and gausemycin A (5), which have been identified by high-resolution mass spectrometry and 1D and 2D NMR analyses. The preliminary evaluation of three small-scale extracts (M400, R358 and SGG) against the fish pathogen, Aeromonas salmonicida subsp. achromogenes KELDUR265-87, showed that the R358 extract displayed significant activity. Furthermore, the natural products (1–5) were evaluated against the fish pathogen Aeromonas salmonicida and human pathogens (Stenotrophomonas maltophilia L2125, Staphylococcus aureus ATCC6538P, and S. pneumoniae L44) using a serial dilution assay. Compound 3 displayed activity against Staphylococcus aureus ATCC6538P, S. maltophilia L2125, and S. pneumoniae L44 with MIC values of 6, 32, and 64 µg/mL, respectively. Interestingly, only gausemycin A (5) exhibited considerable inhibition against A. salmonicida with an MIC value of 32 µg/mL, and the activity increased by two-fold when supplemented with 0.45 mM calcium salt, while 2 and 4 showed moderate inhibition against S. maltophilia L2125. The biosynthetic pathways of compounds 1–4 were proposed. This is the first report of specific inhibition of A. salmonicida by 5.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Marine Biodiscovery Centre, Department of Chemistry, University of Aberdeen, Aberdeen AB24 3FX, UK.
- School of Microbiology, University College Cork, College Road, T12 K8AF Cork, Ireland.
- Sustainability Institute, University College Cork, Lee Road, T23 XE10 Cork, Ireland.
- NAICONS, viale Ortles 22/4, 20139 Milan, Italy.
- Interfaculty Institute of Biochemistry, University of Tübingen, 72076 Tübingen, Germany.
- Department of Pharmacy, Philipps University Marburg, 35043 Marburg, Germany.
ORCID-Profile: Emmanuel Tope Oluwabusola, Stephen A Jackson, Marianna Iorio, Lekha Menon Margassery, Giang-Son Nguyen, David J Clarke, Rainer Ebel, Marcel Jaspars, Alan D W Dobson
Förderung
- European Union's Horizon 2020 research and innovation programme
- BBSRC UK ALERT-22 Scheme
- European Union
Zitieren
APA
Oluwabusola, E. T., Jackson, S. A., Brunati, C., Gackstatter, S., Vedder, H., Iorio, M., Chawande, G., Margassery, L. M., Nguyen, G. S., Clarke, D. J., Ebel, R., Jaspars, M., & Dobson, A. D. W. (2025). Integrated Omics-Based Discovery of Bioactive Halogenated Metabolites from the Deep-Sea Streptomyces sp. B188M101. Marine Drugs. https://doi.org/10.3390/md23090362
Vancouver
Oluwabusola ET, Jackson SA, Brunati C, Gackstatter S, Vedder H, Iorio M, et al. Integrated Omics-Based Discovery of Bioactive Halogenated Metabolites from the Deep-Sea Streptomyces sp. B188M101. Marine Drugs. 2025. doi:10.3390/md23090362
BibTeX
@article{Oluwabusola2025,
author = {Oluwabusola, Emmanuel Tope and Jackson, Stephen A and Brunati, Cristina and Gackstatter, Stefanie and Vedder, Hannah and Iorio, Marianna and Chawande, Gargee and Margassery, Lekha Menon and Nguyen, Giang-Son and Clarke, David J and Ebel, Rainer and Jaspars, Marcel and Dobson, Alan D W},
title = {Integrated Omics-Based Discovery of Bioactive Halogenated Metabolites from the Deep-Sea Streptomyces sp. B188M101},
journal = {Marine Drugs},
year = {2025},
doi = {10.3390/md23090362}
}
EUVIMED